[Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)]. 1980

Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori

The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis. This drug was administered to 2 pediatric patients with purulent meningitis at the dose to 50 mg/kg, by intravenous drip infusion over 30 minutes and one shot intravenous injection respectively. When spinal fluid levels were determined, about 15 approximately 30% of the drug concentration in blood was found to transfer to spinal fluid at acute stage. Spinal fluid levels were about 4 approximately 7 micrograms/ml. When 4 pediatric patients with purulent meningitis were treated with the drug, the good results were obtained in all of them. The dose given was 200 approximately 300 mg/kg/day and the dosing duration was 14 approximately 22 days. No adverse reaction was noted, nor abnormal laboratory test values were noted.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008583 Meningitis, Haemophilus Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults. Haemophilus influenzae Meningitis Type B,Hemophilus influenzae Meningitis Type B,Meningitis, Haemophilus influenzae Type F,Meningitis, Haemophilus parainfluenzae,Meningitis, Hemophilus,Meningitis, Hemophilus influenzae Type F,Meningitis, Hemophilus influenzae, Type B,Meninigitis, HiB,Type B Haemophilus influenzae Meningitis,Type B Hemophilus influenzae Meningitis,Haemophilus Meningitides,Haemophilus Meningitis,Haemophilus parainfluenzae Meningitides,Haemophilus parainfluenzae Meningitis,Hemophilus Meningitides,Hemophilus Meningitis,HiB Meninigitis,Meningitides, Haemophilus,Meningitides, Haemophilus parainfluenzae,Meningitides, Hemophilus
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005260 Female Females

Related Publications

Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
December 1979, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
November 1979, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
January 1982, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
September 1980, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
January 1982, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
January 1982, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
September 1979, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
December 1979, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
November 1979, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and K Kumagai, and M Hori
November 1979, The Japanese journal of antibiotics,
Copied contents to your clipboard!